QQQ $ 482.88 $ 2.24 (0.47 %)
DIA $ 408.91 $ 0.43 (0.11 %)
SPY $ 560.81 $ 1.92 (0.34 %)
TLT $ 98.72 $ 0.06 (0.06 %)
GLD $ 232.16 $ -0.31 (-0.13 %)
$ 0.4376
-- x --
-- x --
-- - --
$ 0.42 - $ 3.28
344,579
na
33.69M
$ -17.89
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 06-21-2021 04-30-2021 10-Q
2 03-17-2021 01-31-2021 10-Q
3 12-21-2020 10-31-2020 10-Q
4 11-13-2020 07-31-2020 10-K
5 06-22-2020 04-30-2020 10-Q
6 03-20-2020 01-31-2020 10-Q
7 12-16-2019 10-31-2019 10-Q
8 11-12-2019 07-31-2019 10-K
9 06-19-2019 04-30-2019 10-Q
10 03-25-2019 01-31-2019 10-Q
11 12-24-2018 10-31-2018 10-Q
12 10-26-2018 07-31-2018 10-K
13 06-11-2018 04-30-2018 10-Q
14 03-16-2018 01-31-2018 10-Q
15 12-14-2017 10-31-2017 10-Q
16 10-26-2017 07-31-2017 10-K
17 06-15-2017 04-30-2017 10-Q
18 03-22-2017 01-31-2017 10-Q
19 01-18-2017 10-31-2016 10-Q
20 01-13-2017 07-31-2016 10-K
21 07-22-2016 01-31-2016 10-Q
22 07-22-2016 04-30-2016 10-Q
23 01-14-2016 10-31-2015 10-Q
24 10-09-2015 07-31-2015 10-K
25 06-05-2015 04-30-2015 10-Q
26 03-06-2015 01-31-2015 10-Q
27 12-12-2014 10-31-2014 10-Q
28 10-03-2014 07-31-2014 10-K
29 06-06-2014 04-30-2014 10-Q
30 03-07-2014 01-31-2014 10-Q
31 12-09-2013 10-31-2013 10-Q
32 10-11-2013 07-31-2013 10-K
33 06-10-2013 04-30-2013 10-Q
34 03-11-2013 01-31-2013 10-Q
35 12-10-2012 10-31-2012 10-Q
36 10-15-2012 07-31-2012 10-K
37 06-11-2012 04-30-2012 10-Q
38 03-12-2012 01-31-2012 10-Q
39 12-12-2011 10-31-2011 10-Q
40 10-14-2011 07-31-2011 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

- Reuters

Core News & Articles

-Reuters

 generex-biotech-reports-fda-accept-pre-investigational-new-drug-briefing-packaging-for-cos-ii-key-sars-cov-2-vaccine-will-give-written-response-by-aug-24

Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced t...

 generex-subsidiary-ngio-advances-covid-19-vaccine-program-with-the-manufacturing-of-patent-pending-ii-key-sars-cov-2-peptides

NuGenerex Immuno-Oncology (NGIO) is focused on modulation of the immune system to develop Ii-Key peptide vaccines for the tre...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION